The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

The purpose of the study is to determine whether the first antibiotic combination works as well as, or better than, the second combination while being safe for patients. After enrollment, participants are randomly assigned to receive one of the two treatment regimens, which are started soon after hospital admission and continued for several days as decided by the treating doctors. Patients remain in the hospital for monitoring and are followed for about a month after the start of treatment.

Researchers will record whether a patient dies from any cause within 30 days and will check for signs of sudden loss of kidney function, known as acute kidney injury, during the same period. Kidney injury is identified when the kidneys stop filtering waste as well as they should, which can be detected through routine blood tests.

The purpose of the study is to see whether a higher radiation dose improves overall survival. Participants will be randomly assigned to receive either the standard radiation dose or a higher dose, then all will continue with the same durvalumab treatment. The study follows patients for several months, checking how long they live, how the cancer responds, any side effects, and how they feel in daily life.

The purpose of the study is to determine how well this imaging test can identify the original location of the cancer and any spread, as well as to assess its ability to detect cancer that may return after treatment. Participants will receive an injection of the radioactive substance, wait a short period for it to circulate, and then undergo the scan. A follow‑up scan may be performed later to see any changes. “Staging” means finding the size and spread of cancer at diagnosis, while “restaging” refers to checking again after therapy. “Sensitivity” describes the test’s ability to correctly find cancer when it is present, “specificity” means correctly showing no cancer when it is absent, “predictive values” indicate how likely the results are to be correct, and “accuracy” reflects the overall correctness of the test.

The scan results will be compared with the tissue analysis that doctors perform after surgery to see if they match. The study will also look at whether the imaging changes the doctor’s view of the cancer stage, leads to different treatment choices, or reveals unexpected findings. Throughout the study, safety checks will be carried out to ensure that the injection and scanning procedure are well tolerated.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

Participants will first undergo screening tests, then receive a single infusion of the modified cells. After the infusion, they will have regular clinic visits where blood samples are drawn and simple health questionnaires are completed to monitor for any side effects and to check if platelet or red‑cell numbers improve. Follow‑up continues for several months to observe how long any benefit lasts and to record any additional medical support needed. Throughout the study, doctors will watch for any unusual lab results or symptoms and will provide standard medical care as needed.

The purpose of the trial is to determine whether AZD8965 can reduce the loss of lung function compared with placebo, using the change in FVC (forced vital capacity, the amount of air exhaled forcefully after a deep breath) as the main measure over about 24 weeks. Participants will be screened, then randomly assigned to receive either the study drug or placebo for a six‑month period, with regular clinic visits for safety checks, blood samples, and simple breathing tests. Throughout the study, any side effects and overall health will be closely monitored.

Participants will take a daily film‑coated tablet for about 40 weeks and will attend regular clinic visits where blood samples are taken to measure HbA1c (a test that shows average blood sugar over the past few months), Fasting plasma glucose (blood sugar after not eating), and will record their own readings using self‑monitoring of blood glucose. Weight, systolic and diastolic blood pressure will also be checked. The study follows a double‑blind design, meaning neither the participants nor the researchers know which pill is being taken until the study ends.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

The purpose is to compare the safety and effectiveness of Surovatamig plus rituximab with the standard chemotherapy plus rituximab in people who have not been treated for Follicular Lymphoma. The study begins with a short safety phase to find a suitable dose, followed by a larger phase where participants receive treatment cycles over several months. Throughout the trial, regular doctor visits, blood tests and imaging scans are performed to watch for side effects and to see how the disease responds.

The purpose of the study is to determine whether stopping long‑term aspirin in this population is not worse than continuing it for overall health outcomes. Participants will be randomly assigned to either keep taking aspirin or to receive a harmless tablet that looks the same but contains no active drug (placebo). The study will follow participants for several years, checking in at regular intervals.

During the follow‑up, researchers will record events such as cardiovascular death, fatal bleeding, intracranial bleeding, ischemic stroke, MI and other serious bleeding problems, as well as less severe issues like peptic ulcer, angina, and overall quality of life. The information collected will help decide if stopping aspirin is a safe option for older adults with stable heart disease.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The purpose of the study is to see whether a single dose of the medication can trigger migraine attacks in this group of women. After taking the tablet, participants will stay in a comfortable setting where their headache intensity, any occurrence of headache, heart rate (the number of beats per minute), and mean arterial pressure (a measure of overall blood pressure) will be recorded at regular intervals. Any side effects or unwanted symptoms that appear during the observation period will also be noted.

Participants may receive one of several study medicines: an oral tablet called ibrutinib, an oral capsule named zanubrutinib, an intravenous infusion of linvoseltamab, a subcutaneous injection (under the skin) of elranatamab, a subcutaneous injection of teclistamab, or a subcutaneous injection of talquetamab. Oral medicines are taken by mouth, while the infusion is given through a vein and the injections are placed just under the skin. Each medication is given at a specific dose that is determined by the study plan.

People are randomly assigned to receive one of the medicines and are followed for a period of time with regular clinic visits, blood tests, and health questionnaires. Throughout the study, researchers track how long participants live (called overall survival) and other health outcomes such as disease progression and quality of life, while also monitoring for any side effects.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The primary aim is to evaluate how well this combination works in controlling the disease. Participants receive the injection and the capsule on a repeated schedule, typically every few weeks, and are followed for several months with regular doctor visits, blood tests, and imaging to check for disease activity and any side effects. The study continues until a predefined number of treatment cycles are completed or if a participant experiences significant toxicity that requires stopping the therapy.

Participants are randomly assigned to receive either tablets containing 1800 mg of thiamine hydrochloride or matching placebo tablets for a period of four weeks. The trial is conducted in a double-blind manner, meaning that neither the participants nor the study staff know which tablets are being taken. Study visits include an initial assessment, regular check‑ins, and a final evaluation after the treatment period.

The purpose is to compare the effect of high dose thiamine with placebo on changes in fatigue as measured by the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional-Questionnaire global score from the start of the study to week 4.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants are randomly assigned to receive either a daily oral pill such as edoxaban or apixaban, an injectable medicine such as dalteparin, tinzaparin, enoxaparin, or rivaroxaban, or a placebo that looks the same but contains no active drug. Over several months, they will have regular check‑ups that may include simple scans of the lungs to confirm whether the clot has changed, and they will complete questionnaires about their daily well‑being. The study does not require any special procedures beyond the usual care for cancer and clot management.

Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

People in the study will have either closed wounds, such as stitched cuts, or open wounds, such as small biopsy wounds made during the study. After treatment, the wounds will be followed over time while they heal, and the scars will be checked later. The study will also look at how safe the treatment is and whether any side effects occur, such as skin reactions or other body reactions. Some scars will also be looked at with medical pictures and ultrasound, which is a test that uses sound waves to create images inside the body.

Scar prevention is the main focus of this trial, and the study is designed to compare three verteporfin doses with saline in both open and closed wound types. The study will continue until the healing and scar checks are completed after treatment.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

At the start, pembrolizumab is given over a period of time, with regular medical checks during treatment. After treatment, the cancer is checked again with tests such as a CT scan, which is a special X-ray picture of the body, and an endoscopy, which is a thin tube test used to look inside the bowel. Based on these results, some people may go on to surgery, while others may be monitored closely without immediate surgery. The study also follows health over time to learn about possible side effects, recovery, and general well-being.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.

The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.

For those with a high amount of the protein, AZD5335 will be compared to mirvetuximab soravtansine. For those with a low amount of the protein, AZD5335 will be compared to a treatment chosen by the doctor, which may include doxorubicin hydrochloride, liposomal, topotecan, or paclitaxel. These treatments are delivered through an intravenous infusion, which means the medicine is passed directly into a vein.

During the study, participants will receive their assigned treatment and will be monitored to see how long the cancer remains stable without growing. This period is referred to as progression-free survival. The study also looks at overall survival, which is the total length of time from the start of the study until death from any cause.

During the study, women will be given either pitolisant or a placebo, which is an inactive substance containing gelatin, in the form of an oral tablet. The research will observe how the administration of these substances affects the frequency and intensity of headache symptoms over a period of time.

During the study, participants will be monitored to see how well the different antibiotic treatments work to clear the infection and reduce symptoms such as fever. The course of the study involves comparing the effectiveness of the oral and injection combination against the existing hospital methods to determine if the new approach is just as effective in achieving a clinical cure.

Participants in the study will be assigned to one of the two treatment groups through a process called randomization, which is similar to drawing lots to decide which group a person joins. To ensure the results are unbiased, a double-blind method is used, meaning that neither the participants nor the researchers know which specific treatment is being given during the course of the study. The study will monitor how long the cancer remains stable and how long participants live to determine if the new combination is more effective than the current standard treatment.

During the study, participants will be assigned to different groups to receive either the combination of LY4268989 and mirikizumab or mirikizumab alone. The process is double-blind, meaning neither the participants nor the researchers know which specific treatment is being administered. The course of the study involves monitoring the participants over a 12-week period to observe how they respond to the medications.

During the trial, participants are assigned to receive either AZD0292 or a placebo. The study is double-blind, meaning that neither the participants nor the researchers know which treatment is being administered until the study is finished. The research will monitor how the medication moves through the body, a process known as pharmacokinetics, and track any pulmonary exacerbations, which are sudden increases in symptoms like coughing or shortness of breath. Participants will be monitored over a period of time to observe how the treatment affects the frequency of these lung symptom flare-ups.

The study is designed to see which treatment approach helps patients live longer, which is referred to as overall survival. Other factors being looked at include progression-free survival, which is the length of time during and after treatment that a disease does not get worse, and the time it takes for a disease to begin growing again. The study also monitors how the body responds to the medicine and any changes in symptoms like cough, chest pain, or dyspnea, which is the medical term for shortness of breath.

During the trial, participants are assigned to different groups to receive either the combination of medicines or a single medicine. Researchers will track how the drugs affect the body and any adverse events, which are unexpected or unpleasant side effects that occur during treatment. The study will also examine the amount of medicine present in the blood and how the body’s health and quality of life change over time.

The investigation is divided into two parts to first determine the most appropriate amount of the medicine to give and then to see how well it works. The medication is administered as a subcutaneous injection, which is a type of injection given into the fatty tissue just under the skin. Participants will receive the treatment for a series of cycles to monitor how the disease responds over time.

Participants will be assigned to receive either dapagliflozin or a placebo in the form of an oral tablet. Throughout the study, various health factors will be monitored, such as eGFR, which is a measure used to check how well the kidneys are filtering blood, and proteinuria, which is the presence of excess protein in the urine. Other areas of interest include monitoring creatinine levels, a waste product in the blood that indicates kidney health, and checking for cholesterol levels. The study will also track blood pressure, the force of blood against artery walls, and the occurrence of any urinary tract infection.

The research will continue for a set period to observe changes in health outcomes. This includes monitoring for kidney transplant rejection, where the body’s immune system attacks the new organ, and checking for end-stage renal disease, a condition where the kidneys can no longer support the body’s needs. Additionally, the study will track major adverse cardiac events, which are serious heart-related problems, and general safety through the reporting of adverse events. The participants will receive regular follow-ups to ensure all necessary measurements are taken over the course of the trial.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.